Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. FDA Says Chinese Supplier Of Heparin API Never Inspected

This article was originally published in PharmAsia News

Executive Summary

The U.S. FDA blames human error and other problems for never inspecting the facilities of a Chinese supplier of active ingredients contained in Baxter International's heparin product. The product has been linked to four deaths and hundreds of allergic reactions. An FDA spokeswoman said the agency inspected the Baxter facility in New Jersey where the finished version of the drug was made, but because of a series of errors, the Chinese plant was never inspected. She said the agency is preparing to inspect the Chinese facility, which was not identified, as soon as possible. (Click here for more - a subscription may be required

You may also be interested in...

Congressman Calls For Resignation Of U.S. FDA Commissioner In Wake Of Latest Chinese Safety Scare

A key House subcommittee chairman has called for the resignation of U.S. FDA Commissioner Andrew von Eschenbach in the wake of reports that FDA failed to inspect a Chinese API manufacturer that may be linked to adverse reactions in patients taking injectable heparin, a blood thinner marketed by Baxter Healthcare (PharmAsia News, Feb. 14, 2008)

Mark Cuban ‘Very Involved’, Insists Generics Company CEO

Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.

Bharat Biotech To Make GSK’s Malaria Vaccine For WHO

GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts